Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
180
-
Total 13F shares, excl. options
-
111M
-
Shares change
-
+17.5M
-
Total reported value, excl. options
-
$1.51B
-
Value change
-
+$246M
-
Put/Call ratio
-
0.27
-
Number of buys
-
118
-
Number of sells
-
-52
-
Price
-
$13.58
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2020
208 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2020.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111M shares
of 236M outstanding shares and own 46.95% of the company stock.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (15M shares), BlackRock Inc. (11.4M shares), VANGUARD GROUP INC (7.32M shares), WELLINGTON MANAGEMENT GROUP LLP (7.27M shares), Consonance Capital Management LP (7.03M shares), Nantahala Capital Management, LLC (6.1M shares), ABRAMS CAPITAL MANAGEMENT, L.P. (5.66M shares), STATE STREET CORP (5.01M shares), GREAT POINT PARTNERS LLC (3.51M shares), and D. E. Shaw & Co., Inc. (2.32M shares).
This table shows the top 180 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.